3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
71
Prostatic Neoplasms
22
Kidney Neoplasms
14
Carcinoma, Transitional Cell
9
Urinary Bladder Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Neoplasm Metastasis
6
Clear-cell metastatic renal cell carcinoma
6
Carcinoma, Hepatocellular
6
Urethral Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
4
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Wilms Tumor
2
Urologic Neoplasms
2
Urogenital Neoplasms
2
Ureteral Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Recurrence
2
Penile Neoplasms
2
Pancreatic Neoplasms
2
Pain
2
Osteosarcoma
2
Melanoma
2
Interventions
belzutifan
2
Everolimus
2
Blood Specimen Collection
2
tanespimycin
1
spartalizumab
1
palbociclib
1
lenvatinib
1
cabozantinib
1
Sunitinib
1
PT2385
1
Oxygen-15
1
Nivolumab
1
Fluorodeoxyglucose F18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
cabozantinib
×
Genitourinary
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled